AML patients with intermediate risk cytogenetics but neither with favorable cytogenetics nor with unfavorable cytogenetics had the highest percentage of STAG2 and RAD21 mutation, and accord with the previous result (11). The gene discussed is STAG2; the disease is acute myeloid leukemia.